Despite most of the prolactinomas can be treated with endocrine therapy and/or surgery, a
significant percentage of these tumors can be resistant to endocrine treatments and/or recur …

Prolactinomas account for approximately 40% of all pituitary adenomas and are an
important cause of hypogonadism and infertility. The ultimate goal of therapy for …

Review the medical and surgical management of patients with prolactinomas and provide
an in-depth appraisal of the role of radiotherapy in the treatment of prolactinomas. A …

Radiotherapy, conventional or radiosurgery, has been used to control prolactin secretion
and tumour growth in prolactinomas both as part of multimodal therapy or rarely as primary …

Aggressive pituitary adenomas are notoriously difficult to manage due to their size,
invasiveness, speed of growth and high frequency of recurrence. Except for prolactinomas …

Introduction Treatment of prolactinomas with dopamine agonists has been the established
first-line treatment option for many years, with surgery reserved for refractory cases or …

Pituitary lactotrophs secrete prolactin. This process is enhanced by estrogen and inhibited
by dopamine. Prolactinomas are benign neoplasms that rarely increase in size and are …

Abstract Pituitary tumors represent 10–15% of all intracranial tumors; of these, prolactinomas
account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists …

Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET),
representing approximately half of such tumors. Dopamine agonists (DAs) have traditionally …

Background Temozolomide is an oral alkylating agent with schedule-dependent antitumor
activity against high-grade malignancies including high-grade glioma. Increasingly, reports …